Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Lois A. Daamen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9227-7178; OpenAlex author ID A5071798797. Sources: OpenAlex.

Their work

Papers
84 (first author 14, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
183
Papers, trials and grants by year

2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: 5 papers · 2022: 10 papers · 2023: 7 papers · 2024: 17 papers · 2025: 22 papers · 2026: 18 papers

Papers 50 of 84

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  3. Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real-World Population. Co-author DOI 10.1002/jso.70391↗
  4. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  5. The impact of lower household income and distance to hospital on treatment and survival in patients with localized pancreatic adenocarcinoma. First author DOI 10.1016/j.ejca.2026.116956↗
  6. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Last author DOI 10.1016/j.ejca.2026.117776↗
  7. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  8. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  9. Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study. Co-author DOI 10.1016/j.hpb.2026.08.011↗
  10. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  11. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Co-author DOI 10.1093/bjs/znag122↗
  12. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  13. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532↗
  14. Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Last author DOI 10.1097/sla.0000000000006660↗
  15. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  16. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  17. ASO Author Reflections: The Impact of Perioperative Treatment on Recurrence Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18798-1↗
  18. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  19. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  20. Prehabilitation Targets Associated with the Omission of Adjuvant Chemotherapy After Surgery for Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01357-y↗
  21. Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2025.102969↗
  22. Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. Co-author DOI 10.1016/j.eclinm.2024.103068↗
  23. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Co-author DOI 10.1016/j.ejca.2025.115385↗
  24. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  25. Quality of Life and Toxicity in Patients With Pancreatic Ductal Adenocarcinoma Treated With Online Adaptive Stereotactic Magnetic Resonance Guided Radiation Th… Co-author DOI 10.1016/j.ijrobp.2025.03.046↗
  26. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  27. Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis. Co-author DOI 10.1093/jnci/djae294↗
  28. Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration. Co-author DOI 10.1093/jnci/djaf037↗
  29. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  30. Evaluation of Short and Long-term Outcomes After Resection in Patients With Locally Advanced Versus (Borderline) Resectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006289↗
  31. Defining the Minimal and Optimal Thresholds for Lymph Node Resection and Examination for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: A M… Last author DOI 10.1097/sla.0000000000006295↗
  32. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000006320↗
  33. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  34. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  35. Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An Internation… Last author DOI 10.1245/s10434-024-16649-z↗
  36. ASO Author Reflections: Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Early Recurrence and Patient-Tailored Management. Last author DOI 10.1245/s10434-024-16810-8↗
  37. Association Between Adjuvant Therapy and Survival in Resected Pancreatic Ductal Adenocarcinoma After Different Types and Durations of Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17439-x↗
  38. Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y↗
  39. The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells14090632↗
  40. Quantification of Signal Transduction Pathway Activity in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/ijms262311385↗
  41. Radiation response assessment of organoids derived from patients with pancreatic cancer. Last author DOI 10.1016/j.ctro.2024.100829↗
  42. The Use of MR-Guided Radiation Therapy for Pancreatic Cancer. Co-author DOI 10.1016/j.semradonc.2023.10.002↗
  43. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Co-author DOI 10.1093/jnci/djae166↗
  44. Response to: Comment on "Dynamics of Serum CA 19-9 in Patients Undergoing Pancreatic Cancer Resection". First author DOI 10.1097/as9.0000000000000399↗
  45. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection. Last author DOI 10.1097/sla.0000000000005977↗
  46. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  47. Total versus Partial Pancreatectomy in Patients with Pancreatic Cancer Arising from Multifocal or Diffuse Intraductal Papillary Mucinous Neoplasia - A Multicen… Co-author DOI 10.1097/sla.0000000000006538↗
  48. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  49. Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer. Co-author DOI 10.1111/jgh.16686↗
  50. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗

Closest collaborators

The 25 strongest of 183 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Izaak Quintus Molenaar · 68 shared papers, 2017–2026 · strength 11.99
  2. Hjalmar C. van Santvoort · 57 shared papers, 2017–2026 · strength 9.68
  3. Marc G. Besselink · 56 shared papers, 2017–2026 · strength 9.41
  4. Martijn W.J. Stommel · 33 shared papers, 2019–2026 · strength 5.14
  5. Bas Groot Koerkamp · 31 shared papers, 2019–2026 · strength 4.80
  6. Ignace H. J. T. de Hingh · 31 shared papers, 2021–2026 · strength 4.75
  7. Vincent P. Groot · 26 shared papers, 2017–2026 · strength 4.67
  8. Ammar A. Javed · 22 shared papers, 2024–2026 · strength 4.58
  9. Joseph R. Habib · 22 shared papers, 2023–2026 · strength 4.50
  10. Paul C. M. Andel · 22 shared papers, 2024–2026 · strength 4.30
  11. Vincent Erwin de Meijer · 27 shared papers, 2021–2026 · strength 4.20
  12. Ingmar Florin Rompen · 18 shared papers, 2024–2026 · strength 3.69
  13. Sebastiaan Festen · 24 shared papers, 2021–2026 · strength 3.56
  14. Iris W.J.M. van Goor · 20 shared papers, 2021–2026 · strength 3.29
  15. Robert C. Verdonk · 18 shared papers, 2022–2026 · strength 3.10
  16. Thijs J. Schouten · 18 shared papers, 2021–2026 · strength 3.08
  17. Geert Kazemier M · 19 shared papers, 2021–2026 · strength 2.83
  18. Johanna W. Wilmink · 16 shared papers, 2019–2026 · strength 2.81
  19. Bert A. Bonsing · 18 shared papers, 2021–2026 · strength 2.76
  20. Christopher Lee Wolfgang · 13 shared papers, 2023–2026 · strength 2.64
  21. Jin Peng He · 12 shared papers, 2023–2026 · strength 2.31
  22. Gert J. Meijer · 14 shared papers, 2021–2026 · strength 2.25
  23. Hanneke W.M. van Laarhoven · 13 shared papers, 2019–2026 · strength 2.16
  24. Judith de Vos‐Geelen · 11 shared papers, 2023–2026 · strength 2.11
  25. Casper H.J. van Eijck · 12 shared papers, 2021–2026 · strength 2.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.